Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

摘要

An algorithmic treatment approach to a newly diagnosed patient with chronic myeloid leukemia in chronic phase (CML-CP). second-generation tyrosine kinase inhibitor, adverse event, allogeneic hematopoietic stem cell transplantation, deep molecular response, treatment-free remission. *See text for details